[1] [1] Del Buono MG, Moroni F, Montone RA, et al. Ischemic cardiomyopathy and heart failure after acute myocardial infarction[J]. Curr Cardiol Rep, 2022, 24(10): 1505-1515.

[3] [3] Conti N, Gatti M, Raschi E, et al. Evidence and current use of levosimendan in the treatment of heart failure: filling the gap[J]. Drug Des Devel Ther, 2021, 15: 3391-3409.

[4] [4] Papp Z, Agostoni P, Alvarez J, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use[J]. J Cardiovasc Pharmacol, 2020, 76(1): 4-22.

[5] [5] Masarone D, Kittleson MM, Pollesello P, et al. Use of levosimendan in patients with advanced heart failure: an update[J]. J Clin Med, 2022, 11(21): 6408.

[6] [6] Rysz S, Lundberg J, Nordberg P, et al. The effect of levosimendan on survival and cardiac performance in an ischemic cardiac arrest model-a blinded randomized placebo-controlled study in swine[J]. Resuscitation, 2020, 150: 113-120.

[7] [7] Ayala R, Gewehr DM, Godoi A, et al. Preoperative levosimendan in patients with severe left ventricular dysfunction undergoing isolated coronary artery bypass grafting: a meta-analysis of randomized controlled trials[J]. J Cardiothorac Vasc Anesth, 2024, 38(3): 649-659.

[9] [9] Burkhoff D, Rich S, Pollesello P, et al. Levosimendan-induced venodilation is mediated by opening of potassium channels[J]. ESC Heart Fail, 2021, 8(6): 4454-4464.

[10] [10] Faisal SA, Apatov DA, Ramakrishna H, et al. Levosimendan in cardiac surgery: evaluating the evidence[J]. J Cardiothorac Vasc Anesth, 2019, 33(4): 1146-1158.

[11] [11] Bruno RR, Kelm M, Jung C. Pharmaceutical therapy of infarct-related cardiogenic shock[J]. Dtsch Med Wochenschr, 2022, 147(18): 1173-1182.

[12] [12] Rababa'h AM, Khabour OF, Alzoubi KH, et al. Assessment of genotoxicity of levosimendan in human cultured lymphocytes[J]. Curr Mol Pharmacol, 2019, 12(2): 160-165.

[13] [13] Demirgan S, Akyol O, Temel Z, et al. Intranasal levosimendan prevents cognitive dysfunction and apoptotic response induced by repeated isoflurane exposure in newborn rats[J]. Naunyn Schmiedebergs Arch Pharmacol, 2021, 394(7): 1553-1567.

[19] [19] Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure[J]. JACC Heart Fail, 2013, 1(2): 103-111.

[20] [20] Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure[J]. Circulation, 2000, 102(18): 2222-2227.

[24] [24] Tumminello G, Cereda A, Barbieri L, et al. Meta-analysis of placebo-controlled trials of levosimendan in acute myocardial infarction[J]. J Cardiovasc Dev Dis, 2021, 8(10): 129.

[25] [25] Zhang X, Wang ZS, Zhang L, et al. Comparative effectiveness and safety of intermittent, repeated, or continuous use of levosimendan, milrinone, or dobutamine in patients with advanced heart failure: a network and single-arm meta-analysis[J]. J Cardiovasc Pharmacol, 2024, 84(1): 92-100.

[28] [28] Elsherbini H, Soliman O, Zijderhand C, et al. Intermittent levosimendan infusion in ambulatory patients with end-stage heart failure: a systematic review and meta-analysis of 984 patients[J]. Heart Fail Rev, 2022, 27(2): 493-505.

[29] [29] Fernando SM, Mathew R, Sadeghirad B, et al. Inotropes, vasopressors, and mechanical circulatory support for treatment of cardiogenic shock complicating myocardial infarction: a systematic review and network meta-analysis[J]. Can J Anaesth, 2022, 69(12): 1537-1553.

[30] [30] Garca-Gonzlez MJ, Aldea Perona A, Lara Padron A, et al. Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study[J]. ESC Heart Fail, 2021, 8(6): 4820-4831.

[31] [31] Altenberger J, Gustafsson F, Harjola VP, et al. Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications[J]. J Cardiovasc Pharmacol, 2018, 71(3): 129-136.

[35] [35] Jaguszewski MJ, Gasecka A, Targonski R, et al. Efficacy and safety of levosimendan and dobutamine in heart failure: a systematic review and meta-analysis[J]. Cardiol J, 2021, 28(3): 492-493.